Vogenx, Inc.

Vogenx, Inc. (VOGX) priced its initial public offering on Aug 12, 2026 at $13.00 per share, within its $11.00–$13.00 range, raising $81.2M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $180.9M. Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan advised the company and Sichenzia Ross Ference Carmel advised the underwriters.

Vogenx, Inc. is a clinical-stage biopharmaceutical company developing therapies for metabolic dysfunction, including post-bariatric hypoglycemia and gastroparesis. Its lead candidate is mizagliflozin, a selective inhibitor of the sodium-glucose transporter SGLT1.

Status

IPO

Ticker

VOGX

Exchange

Nasdaq Capital Market

Priced

Aug 12, 2026

IPO price

$13.00

Price range

$11.00–$13.00

Raised

$81.2M

Market cap at IPO price

$180.9M

First filed

Jul 15, 2026

Company counsel

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan

Underwriters' counsel

Sichenzia Ross Ference Carmel

Sector

Biotech & pharma

Country / state

NC

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.